Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=-start_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-start_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-start_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-start_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-start_date" }, "data": [ { "type": "Grant", "id": "15676", "attributes": { "award_id": "1F32HD116425-01A1", "title": "Developing a Biomimetic Lactating Mammary Lobe for Therapeutic Safety", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 32520, "first_name": "KATIE MARIE", "last_name": "VANCE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-04-01", "end_date": "2027-07-31", "award_amount": 76756, "principal_investigator": { "id": 32521, "first_name": "Amy H", "last_name": "Lee", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 210, "ror": "https://ror.org/042nb2s44", "name": "Massachusetts Institute of Technology", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY. Breast milk is rich with bioactive components that are critical to an infant’s development. It is highly recommended that infants ingest breast milk; but, fluctuating maternal hormones and substandard post-parturition health directly mediate breast milk production. Maternal ingestion of small molecule drugs further compounds decreased breast milk synthesis and secretion, and adversely compromises breast milk quality. Although the majority of actively breastfeeding women consume medication or receive therapeutics, small drug molecule transport from maternal plasma to synthesized breast milk remains largely unknown. Important strides in understanding pharmacokinetics in milk-producing mammary glands have yet to occur because of the lack of engineered bioinspired mammary lobe systems that mimic complex in vivo signatures— topographical lobule microcurves, spiked levels of lactogenic hormones, cellular landscapes, and mechanically-driven lobe expansion and contraction. The objective of this proposal is to determine if our established microengineered mammary lobe system, which integrates key physiological characteristics, i.) faithfully mirrors multifactorial breast milk synthesis processes and ii.) could be employed as a versatile screening testbed for evaluating drug and therapeutic safety during lactation. The project is based on the central hypothesis that exogenous stimuli that reflect in vivo mechanisms, such as hormone levels, dynamic mechanical lobe stimulation, and passive transport of small drug molecules, will potentiate differential cellular landscape phenotypes and lead to unique content differences in engineered breast milk. This could develop a new in vitro preclinical model that promotes the cognizance of drugs or therapeutics that are safe to ingest or receive during lactation. We believe this contributes to improving important women’s health issues. Our hypothesis will be tested through the following two aims. Aim 1 will develop a 3D mammary lobe model and determine how in vivo relevant parameters alter physical and molecular mammary cell phenotypes, and regulate the secretion of important breast milk components. Aim 2 will investigate the pharmacokinetics of small molecule drugs or therapeutics that passively diffuse into the engineered breast milk. Nicotine or mRNA encoding for SARS-CoV-2 will serve as a model drug or therapeutic, respectively. We will pursue these aims using an innovative combination of analytical and adaptable techniques from engineering and biological sciences. These include the development of a scalable lobe model, by which the application of physiologically relevant stimuli and compartments can mimic breast milk synthesis and drug distribution. The engineering approaches that we leverage will develop foundational resources for the ongoing efforts and research revolving lactation and post-parturition health equity. The expected outcome of this work will highlight the importance of engineering new microsystems for in vivo mimicry. These platforms can facilitate clinical translation of rapid drug and therapeutic safety screening. The results will have a significant positive impact to women and will encourage the ongoing efforts to support women during their breastfeeding journey.", "keywords": [ "2019-nCoV", "3-Dimensional", "Affect", "Air", "Apical", "Biological Sciences", "Biomimetics", "Birth", "Breast Feeding", "COVID-19", "COVID-19 vaccine", "Carrier Proteins", "Caseins", "Cell Polarity", "Cell Proliferation", "Cell-Cell Adhesion", "Cells", "Characteristics", "Chemicals", "Circulation", "Complex", "Consumption", "Cultured Cells", "Cytoskeletal Proteins", "Development", "Diffuse", "Diffusion", "Drug Kinetics", "Drug Modelings", "Engineering", "Enzyme-Linked Immunosorbent Assay", "Excretory function", "Exhibits", "Exposure to", "Gland", "Goals", "Harvest", "Health", "High Pressure Liquid Chromatography", "Hormones", "Human Milk", "In Vitro", "Individual", "Infant", "Infant Development", "Ingestion", "Lactation", "Lipids", "Lobe", "Lobule", "Mammary gland", "Maternal health equity", "Mechanical Stimulation", "Mechanical Stress", "Mechanics", "Mediating", "Membrane", "Messenger RNA", "Milk Proteins", "Mission", "Modeling", "Molds", "Molecular", "Mothers", "Motion", "Nicotine", "Nutrient", "Outcome", "Oxytocin", "Perfusion", "Periodicity", "Pharmaceutical Preparations", "Phenotype", "Physiological", "Plasma", "Pre-Clinical Model", "Pregnancy", "Process", "Prolactin", "Protein Biosynthesis", "Protein Secretion", "Proteins", "Proteomics", "Public Health", "Pump", "RNA vaccine", "Recommendation", "Regulation", "Reporting", "Research", "Resources", "Safety", "Side", "Stains", "Stimulus", "Structure", "Surface", "System", "Techniques", "Testing", "Therapeutic", "Tight Junctions", "United States National Institutes of Health", "Variant", "Ventilator", "Woman", "Women&apos", "s Health", "Work", "clinical translation", "drug distribution", "drug testing", "extracellular vesicles", "health equity", "high throughput screening", "improved", "in vivo", "innovation", "interstitial", "lactogenesis", "lipidomics", "mammary", "maternal vaccination", "mechanical drive", "mechanical properties", "mechanical stimulus", "microsystems", "milk expression", "milk production", "milk secretion", "mimicry", "molecular phenotype", "nicotine use", "passive transport", "pre-clinical", "protein expression", "reconstitution", "screening", "secretory protein", "small molecule", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "15648", "attributes": { "award_id": "2439345", "title": "CAREER: Intelligent Biomarker Analysis based on Wearable Distributed Computing", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "CAREER: FACULTY EARLY CAR DEV" ], "program_reference_codes": [], "program_officials": [ { "id": 12587, "first_name": "Juan", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 340, "ror": "", "name": "North Dakota State University Fargo", "address": "", "city": "", "state": "ND", "zip": "", "country": "United States", "approved": true } ] } ], "start_date": "2025-04-01", "end_date": null, "award_amount": 503930, "principal_investigator": { "id": 32151, "first_name": "Juan", "last_name": "Patarroyo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1024, "ror": "", "name": "University of Puerto Rico Mayaguez", "address": "", "city": "", "state": "PR", "zip": "", "country": "United States", "approved": true }, "abstract": "Some of the challenges associated with wearable technologies are the limitation on computational power, battery capacity, data privacy, user interface design, and the need for seamless integration into user lifestyles without causing discomfort. These challenges limit the on-device implementation of machine learning methods, which are suitable for classifying and estimating medical conditions based on the biomarkers sensed by the wearable devices. This research addresses these problems by developing a scheme that distributes the computational load of machine-learning models across wearable devices. Results from this research contribute to deploying advanced health monitoring tools for in-home care of frail populations, such as post-COVID patients. This is aligned with the NSF mission to promote the progress of science and advance national health. The development of this project involves multidisciplinary efforts from computer science, bioengineering, and electrical engineering, as well as educational activities with the participation of students from underrepresented groups. This project focuses on developing a wearable sensor network scheme with distributed and interconnected computing capabilities. As an application case, the wearable computing sensor network is aimed at biomechanics analysis for frail populations. The research plan is geared toward creating an advanced scheme of wearable devices to improve power consumption, data privacy, and computational performance for advanced health monitoring and analysis. To fulfill the strict requirements of size, computational load, and energy consumption, a novel distributed machine learning architecture is designed and deployed on each wearable sensor using field programmable gate arrays. The deployed architecture is a simplified version of the parallel-computing architecture found in commercial graphics processing units, which have been demonstrated to be suitable for machine-learning applications. In addition, this architecture contains additional hardware components for estimating missing data, synchronization, and addressing communication errors between the devices. This project addresses realistic challenges in biomedical and wearable technologies research, including (i) segmenting and training machine learning models considering the nature of biomechanical data and wearable inertial sensors without affecting accuracy, (ii) modeling a lightweight computer architecture for performing distributed machine learning inference in real time, (iii) estimating detailed body motion dynamics using a reduced amount of inertial sensors, and (iv) integrating reliable and state-of-the-art data analytics environments for efficient real-time analysis and visualization. The education plan tackles three major areas: (i) research training and competitive experiences for graduate and undergraduate students in the areas of computer science, computer architecture, and health-related areas, (ii) course development in topics related to edge computing, real-time systems, and machine learning applications to healthcare, and (iii) outreach to K-12 students and professionals by the introduction of competitive activities. Most of the students and contributors for this project are Hispanic, and this project supports broader access to and training in cutting-edge research in computational applications. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15677", "attributes": { "award_id": "1I21BX007163-01", "title": "Development of 12-Lipoxygenase Inhibitors for diabetes treatment.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2025-04-01", "end_date": "2027-03-31", "award_amount": null, "principal_investigator": { "id": 32522, "first_name": "JERRY L.", "last_name": "NADLER", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2157, "ror": "", "name": "VA NORTHERN CALIFORNIA HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Approximately 25% of US Veterans have diabetes and the annual mortality rate due to diabetes in Veterans is almost double of the rate in Veterans without diabetes. The presence of diabetes in the Veteran population is an important cause of disability due to complications such as cardiovascular disease, neuropathy, retinopathy, and kidney disease. Recent studies have indicated higher rates of new onset diabetes in Veterans who have had COVID-19 and analysis of Veterans using the Million Veteran Database indicate a growing identification of new onset type 1 diabetes (T1D) in adults. Almost half of the newly diagnosed cases of T1D are adults and there is an unmet medical need to identify treatments to prevent or halt progression of the disease. 12-lipoxygenase (12-LOX) is a lipid-generating enzyme produced by various sites including pancreatic islet beta cells. 12- LOX expression is elevated in obesity, Type 2 diabetes ( T2D) and T1D. We showed that 12-LOX protein is increased in islets of auto-antibody-positive and Type 1 and Type 2 individuals. 12-LOX products are highly pro-inflammatory and reduce pancreatic beta cell function and viability. 12-LOX lipids lead to oxidative and endoplasmic reticulum stress and macrophage activation. Genetic deletion of 12-LOX in mouse models improves insulin signaling and prevents T1D development. We earlier discovered a highly selective 12-LOX inhibitor, ML-355, through a comprehensive screening, followed by iterative medicinal chemistry optimization. ML-355 has been licensed and pre-clinical and phase 1 safety testing has been successfully completed and found to be safe. ML-355 is in a phase 2 clinical trial for intravenous administration for a hematologic indication as the inhibitor is not sufficiently orally bio-available for chronic diabetes use. We recently discovered a new 12-LOX inhibitor, Slug001, which manifests increased potency both in vitro and in rescuing inflamed human islet cells, relative to ML355. We propose to explore this novel structural space with a suite of modifications of Slug001, guided by our computational modeling of ML355 docking. The goal in Aim 1 is to derivatize Slug001 and fill the active site cavity more efficiently so that the inhibitor potency can be increased more than its current 7-fold improvement relative to ML355 and have improved oral bioavailability. The docking model will greatly enhance the identification of promising new inhibitors. Of the six Slug001 lead derivatives, we have already synthesized several and shown that Slug002 is as potent as Slug001 but has better solubility. The completed studies will generate novel inhibitors and a new VA patent. In Aim 1 of the proposal, we will synthesize the new molecules and measure their potency and selectivity. Established methods, comparing potency with docking scores, will allow us to quickly design these derivatives, increase their potency and then subject them to our human diabetic cellular assays established in Aim 2. The derivatives of Slug001 will be screened by the Holman laboratory against the LOX isozymes (5-LOX, 12-LOX, 15-LOX-1, 15-LOX-2) to establish their selectivity. In Aim 2 we will test the efficacy of the inhibitors in a reliable and novel human functional Islet beta cell line and then move to testing in primary cadaveric human pancreatic islets. The testing will utilize using our established and validated assays to test effects on insulin secretion and protection from cytokine mediated damage. Our expectation at the completion of this pilot, is to move the lead compound (s) into a novel in humanized 12-LOX mouse model of T1D that will facilitate rapid translation to clinical testing. The proposed project will provide a new way to address the high rates of adult-onset Type 1 diabetes and complications in the Veteran population.", "keywords": [ "Acceleration", "Active Sites", "Address", "Adult", "Arachidonate 12-Lipoxygenase", "Arachidonate 15-Lipoxygenase", "Beta Cell", "Biological Assay", "Biological Availability", "Blood Vessels", "COVID-19", "Cadaver", "Cardiovascular Diseases", "Cell Line", "Cell Physiology", "Cell Survival", "Cells", "Cellular Assay", "Characteristics", "Chronic", "Computer Models", "Data", "Databases", "Death Rate", "Derivation procedure", "Development", "Diabetes Mellitus", "Disease Progression", "Docking", "Enzymes", "Generations", "Genetic", "Goals", "Health", "Hematology", "Human", "Immune", "In Vitro", "Individual", "Inflammatory", "Injury", "Insulin Resistance", "Insulin-Dependent Diabetes Mellitus", "Islet Cell", "Islets of Langerhans", "Isoenzymes", "Kidney Diseases", "LOX gene", "Laboratories", "Lead", "Legal patent", "Licensing", "Lipids", "Lipoxygenase Inhibitors", "Machine Learning", "Macrophage", "Macrophage Activation", "Measures", "Mediating", "Medical", "Methods", "Modeling", "Modification", "Neuropathy", "Newly Diagnosed", "Non-Insulin-Dependent Diabetes Mellitus", "Obesity", "Oral", "Pathway interactions", "Pharmaceutical Chemistry", "Phase", "Phase II Clinical Trials", "Population", "Proteins", "Retinal Diseases", "Safety", "Site", "Solubility", "Structure of beta Cell of islet", "Testing", "Translations", "Veterans", "blood glucose regulation", "cell injury", "cytokine", "design", "diabetic", "disability", "efficacy testing", "endoplasmic reticulum stress", "expectation", "improved", "in vivo", "in vivo evaluation", "inhibitor", "insulin dependent diabetes mellitus onset", "insulin secretion", "insulin signaling", "intravenous administration", "islet", "islet cell antibody", "military veteran", "mouse model", "non-diabetic", "novel", "novel therapeutics", "post SARS-CoV-2 infection", "pre-clinical", "prevent", "programs", "research clinical testing", "safety testing", "screening", "small molecule inhibitor", "type I and type II diabetes" ], "approved": true } }, { "type": "Grant", "id": "15604", "attributes": { "award_id": "1R21AI183320-01A1", "title": "Altered protein structures and neoepitopes in lupus neutrophils from dysregulated splicing of messenger RNA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 8447, "first_name": "Jeffrey S.", "last_name": "Rice", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-21", "end_date": "2027-02-28", "award_amount": 256808, "principal_investigator": { "id": 32100, "first_name": "Tomas M", "last_name": "Mustelin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of our research is to better define the molecular mechanisms cause and perpetuate systemic lupus erythematosus (SLE). Based on our discovery that transcripts from a large number of genes are spliced differently in neutrophils from SLE patients compared to neutrophils from healthy donors or COVID-19 patients, we propose a novel hypothesis of SLE pathogenesis, namely that dysregulated mRNA splicing in SLE granulocytes can affect their function and generate (neo)autoantigens not seen by the immune system before. We propose to expand and substantiate the analysis of altered mRNA splicing and begin to search for its cause(s). We will define how specific it is to SLE, understand the relation of altered splicing to sex, age, disease activity, type I interferons, and patient heterogeneity. Our work will also embark on the quest to elucidate why mRNA slicing is dysregulated in SLE. Next, we propose to explore the consequences of altered mRNA splicing in SLE. Although we have high confidence in the alignment of RNAseq reads to support all the splicing events we detect, and the transcripts are present at good read counts, it needs to be demonstrated that at least some are translated into altered proteins. We will continue to use targeted LC-MS/MS to find evidence for those with novel amino acid sequences. The proteolytic processing into antigenic peptides presented on MHC seen by T cells will then be explored. We know the MHC haplotypes of all our donors from the RNAseq data, so can match putative neoepitopes with the right MHC. Our work will clarify whether the production of novel, and perhaps individual, neo-autoantigens are a feature of SLE. If so, the production of such antigenic peptides would drive an immune response against the specific cell type that produces them (rather than all cells expressing the gene), adding a new element of tissue or cell linage-targeting to the autoimmune response. This model also introduces a new avenue for the development of therapeutics: modulating mRNA splicing to eliminate the production of neo-autoantigens. This will only be possible once the mechanism(s) underpinning abnormal splicing have been elucidated.", "keywords": [ "2019-nCoV", "Adaptive Immune System", "Address", "Affect", "Affinity", "Age", "Alleles", "Amino Acid Sequence", "Antigens", "Arginine", "Autoantigens", "Autoimmune Responses", "Autoimmunity", "Behavior", "Binding", "Biological", "COVID-19 patient", "Categories", "Cells", "Computer Analysis", "Data", "Databases", "Dermatomyositis", "Disease", "Disproportionately impacts women", "Elements", "Embryo", "Epitopes", "Event", "Genes", "Goals", "Haplotypes", "Heterogeneity", "Immune", "Immune response", "Immune system", "Individual", "Interferon Type I", "Lupus", "Malignant Neoplasms", "Mass Spectrum Analysis", "Messenger RNA", "Modeling", "Molecular", "Mutation", "Nature", "Nonsense-Mediated Decay", "Organ", "Pathogenesis", "Patients", "Peptides", "Pharmaceutical Preparations", "Post-Translational Protein Processing", "Process", "Production", "Protein Isoforms", "Proteins", "Proteolytic Processing", "Public Health", "RNA Splicing", "RNA Messenger Splicing", "RNA-Binding Proteins", "Race", "Reporting", "Research", "Retroelements", "Rheumatoid Arthritis", "Sampling", "Site", "Sjogren&apos", "s Syndrome", "Slice", "Spliced Genes", "Structure", "Systemic Lupus Erythematosus", "T-Lymphocyte", "Testing", "Tissues", "Transcript", "Translating", "Translations", "Western Blotting", "Work", "anti-tumor immune response", "cell type", "density", "disorder control", "experimental study", "granulocyte", "individual patient", "mRNA Transcript Degradation", "monocyte", "nanomolar", "neutrophil", "novel", "patient subsets", "protein structure", "sex", "therapeutic development", "transcriptome sequencing" ], "approved": true } }, { "type": "Grant", "id": "15598", "attributes": { "award_id": "1R01ES037151-01", "title": "Multi-component INTERLUNG intervention to protect lung health in Nepal", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 11803, "first_name": "Claudia L", "last_name": "Thompson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-19", "end_date": "2030-02-28", "award_amount": 893525, "principal_investigator": { "id": 9093, "first_name": "William", "last_name": "Checkley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Chronic respiratory diseases (CRDs) remain the third leading cause of death worldwide and their incidence is increasing. In 2019, it was estimated that 455 million people worldwide live with a CRD such as asthma, COPD, and chronic bronchitis. CRDs are responsible for 4 million deaths and 103.5 million disability-adjusted life years lost each year. The development and severity of CRDs is attributed to both environmental exposures and infectious causes. Individuals who live in densely populated cities in low- and middle-income countries (LMICs) are disproportionately affected by high levels of ambient particulate matter, indoor exposure to allergens, dust and tobacco smoke, and a high incidence of viral and bacterial infections. Therefore, to have a meaningful impact on the incidence and severity of CRDs, and prevent further lung function decline, a multi- component evidence-based intervention targeting multiple risk factors is needed. We seek to test the implementation and effectiveness of a tailored multi-component evidence-based intervention following a community health worker (CHW)-driven chronic care delivery model to protect lung health over a 40-month period using a Type I hybrid implementation-effectiveness randomized controlled trial in Bhaktapur, Nepal. The multi-component intervention will consist of: reducing environmental risk factors by targeting tobacco smoking through CHW-delivered messaging and education on smoking prevention and smoking cessation, and targeting indoor and ambient air pollution exposures by providing households with HEPA-indoor air purifiers and vacuum cleaners and encourage masking outdoors with N95 respirators when e-notified about days with high ambient air pollution; reducing infectious risks through an CHW-led vaccine campaign for annual influenza, COVID and pneumococcal vaccine in all eligible participants and household members; encouraging use of surgical masks in indoor public spaces during the peak winter season or at home when there are sick household contacts; and, improving physiologic health by encouraging physical activity through CHW- monitored pedometer goals. Aligned with the Consolidated Framework for Implementation Research, we will first conduct human-centered design workshops with community members and healthcare practitioners to tailor the multi-component intervention. We will then screen and identify 800 index participants aged ≥ 9 years (with a pre-bronchodilator FEV1/FVC Z-score ≤ 10th percentile and chronic cough or wheeze (i.e., at-risk participants). We will enroll index participants and household members and assign half of the households to the adapted intervention. Controls will be asked to continue usual care practices. We will evaluate the effect of the intervention on pre-bronchodilator FEV1 Z-score (primary outcome), respiratory symptoms, and evaluate implementation outcomes. We seek to facilitate scale-up of a multi-component intervention that responds to the real-world implementation context to protect lung health in Nepal and other LMICs.", "keywords": [ "Adherence", "Adopted", "Adoption", "Affect", "Air Pollution", "Allergens", "Asthma", "Bacterial Infections", "Behavior", "Bronchodilator Agents", "COVID-19 vaccine", "Cause of Death", "Censuses", "Cessation of life", "Chronic", "Chronic Bronchitis", "Chronic Care", "Chronic Obstructive Pulmonary Disease", "Cities", "Communities", "Community Health Aides", "Consolidated Framework for Implementation Research", "Coughing", "Data", "Development", "Dust", "Education", "Educational workshop", "Effectiveness", "Enrollment", "Environmental Exposure", "Environmental Risk Factor", "Evidence based intervention", "Exposure to", "Future", "Goals", "Government Officials", "Hand", "Health", "Health Care", "Health system", "Home", "Household", "Household Air Pollution", "Hygiene", "Incidence", "Individual", "Indoor Air Pollution", "Inhalation", "Intervention", "Lateral", "Lower respiratory tract structure", "Masks", "Modeling", "Monitor", "N95 mask", "Nepal", "Notification", "Participant", "Particulate Matter", "Perception", "Persons", "Physical activity", "Physiological", "Pneumococcal vaccine", "Policies", "Process", "Pulmonary Function Test/Forced Expiratory Volume 1", "Quality of life", "Questionnaires", "Recommendation", "Research", "Resources", "Respiratory Signs and Symptoms", "Respiratory Tract Infections", "Risk", "Risk Factors", "Seasons", "Self Efficacy", "Self Management", "Service delivery model", "Severities", "Smoking Prevention", "Social outcome", "Spirometry", "Testing", "Tobacco", "Tobacco smoke", "Tobacco smoking behavior", "Vaccination", "Vaccines", "Vacuum", "Viral", "Virus Diseases", "Wheezing", "World Health Organization", "aged", "ambient air pollution", "chronic care model", "chronic respiratory disease", "comparison control", "disability-adjusted life years", "effectiveness-implementation RCT", "effectiveness/implementation hybrid", "eligible participant", "experience", "high efficiency particulate air filter", "human centered design", "implementation context", "implementation evaluation", "implementation outcomes", "implementation science", "improved", "indexing", "indoor air", "indoor exposure", "influenza virus vaccine", "intervention effect", "intervention mapping", "life span", "low and middle-income countries", "lung health", "member", "multi-component intervention", "multidisciplinary", "nicotine replacement", "pedomet" ], "approved": true } }, { "type": "Grant", "id": "15607", "attributes": { "award_id": "7R01AG080583-03", "title": "Effects of Covid-19 Pandemic on Long-Term Care for High Need Older Adults with and without Alzheimer's Disease and Related Dementia.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 9749, "first_name": "PRISCILLA JOY", "last_name": "Novak", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-15", "end_date": "2028-01-31", "award_amount": 584471, "principal_investigator": { "id": 26903, "first_name": "Yulya", "last_name": "Truskinovsky", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 579, "ror": "https://ror.org/025r5qe02", "name": "Syracuse University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Nearly 20 million adults (38%) aged 65 and older have limitations with one or more self-care activities (e.g., dressing, getting out of bed) and one in ten older adults are living with Alzheimer’s Disease and Related Dementias (ADRD). Together these two overlapping groups of “high-need” older adults typically rely on a variety of long-term care (LTC) sources to assist with daily activities, including family and unpaid care, paid care in the home, residential care such as assisted living and nursing home care. Inadequate care may lead to adverse consequences in daily self-care and avoidable health care utilization. The sudden onset of the COVID- 19 pandemic may have profoundly affected access to and use of LTC and contributed to further adverse consequences for high-need older adults, particularly for those living with ADRD. This project will draw upon two complementary longitudinal, nationally representative surveys of older adults–the Health and Retirement Study (HRS) and the National Health and Aging Trends Study (NHATS)–linked to geographic data and Medicare claims. Using statistical approaches that strengthen our ability to draw causal inferences, we will: 1) Evaluate the short-term impact (2018-2020) of the COVID-19 pandemic on the type and amount of LTC use, comparing high-need older adults with and without ADRD and identify arrangements more likely to be “stable” with lower risks of change. 2) Determine whether care trajectories were disrupted after the start of the pandemic, comparing high-need older adults with and without ADRD from 2016 through 2024/2025. 3) Assess the impact of COVID-19 on adverse consequences related to care gaps among high-need older adults with and without ADRD. We will estimate the effect of the COVID-19 pandemic on self-reports of unmet need (using NHATS) and claims-based measures of avoidable hospitalizations and emergency department visits (using HRS) for those with and without ADRD. Detailed geographic data will allow us to take into account local conditions while identifying more “vulnerable” care arrangements with higher risks of adverse consequences. The results of this project will provide a comprehensive understanding of the COVID-19 pandemic’s impact on LTC outcomes in the short and longer term. This study aligns with NIA’s priority to understand community support for dementia care, in particular the determinants of availability LTC, LTC utilization and how the effects of community level factors including infrastructure and risk environment.", "keywords": [ "Address", "Adult", "Affect", "Aging", "Alzheimer&apos", "s disease related dementia", "Area", "Assisted Living Facilities", "Beds", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 pandemic effects", "Caregivers", "Caring", "Cessation of life", "Communities", "Data", "Death Rate", "Dementia", "Emergency department visit", "Environment", "Family", "Family Caregiver", "Generations", "Geography", "Health", "Health Care", "Health and Retirement Study", "Home", "Home Nursing Care", "Hospitalization", "Impaired cognition", "Infrastructure", "Link", "Long-Term Care", "Marketing", "Measures", "Medicare claim", "Nursing Homes", "Patient Self-Report", "Persons", "Public Health", "Reporting", "Research", "Residential Treatment", "Risk", "Self Care", "Services", "Signal Transduction", "Soil", "Source", "Sterile coverings", "Surveys", "Techniques", "Time", "Training", "Variant", "Virus", "Work", "adverse outcome", "aging population", "care outcomes", "community-level factor", "dementia care", "geographic difference", "health care availability", "health care service utilization", "health data", "high risk", "human old age (65+)", "improved", "late life", "long-term COVID-19 pandemic impacts", "mortality risk", "neglect", "older adult", "pandemic disease", "pandemic impact", "pandemic potential", "patient home care", "programs", "resilience", "school closure", "trend" ], "approved": true } }, { "type": "Grant", "id": "15600", "attributes": { "award_id": "1K23AI187708-01", "title": "Active and passive humoral immunity to enteric adenovirus infection in Bangladeshi children", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7031, "first_name": "RUTH HUAB", "last_name": "Florese", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": "2030-02-28", "award_amount": 192260, "principal_investigator": { "id": 32098, "first_name": "Jennifer Marie", "last_name": "Hendrick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 908, "ror": "https://ror.org/0153tk833", "name": "University of Virginia", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Candidate: I am an Assistant Professor at the University of Virginia (UVA) in the Division of Infectious Disease and International Health and a KL2- Funded Scholar in the Integrated Translational Health Research Institute of Virginia (iTHRIV) Scholars Program. I have pursued research in host pathogen immune interactions with Dr. William Petri for the past 6 years. Beginning initially with enteric pathogens and shifting to SARS-CoV-2 during the pandemic, I will now return to my work in diarrheal disease utilizing my background in viral immunology through study of adenovirus (AdV) 40/41 infection, a major cause of childhood diarrheal illness in low- and middle- income countries (LMIC). Career Development Plan/Career Goals & Objectives: My goal is to become an independent translational investigator. I will do so by furthering my knowledge base in the design of clinical trials, host pathogen immune interactions, viral immunology and data analysis. I will utilize my advisory committee who are not only successfully funded researchers but have a proven track record for mentoring young physician scientists. Research Plan: Characterize the systemic and mucosal immune response to AdV 40/41 infection in children in Bangladesh and determine the efficacy breast milk antibodies in providing passive immunity. Aim 1 (PASSIVE IMMUNITY): (1A) Describe the antibody repertoire to AdV 40/41 in the breast milk of mothers of Bangladeshi children using a novel protein microarray and (1B) determine their association with infection in the first 2 years of life. Plan: Determine maternal breast milk antibody breadth and magnitude, and test for its association to infant infection. Aim 2 (ACTIVE IMMUNITY): Characterize the antibody responses to AdV 40/41 infection in Bangladeshi children and test for their association with subsequent infection utilizing longitudinal (2A) serum and (2B) stool samples. Plan: Describe mucosal and systemic antibody scope and magnitude and test for association with protection from subsequent infection. Mentor/Co-Mentor(s), and Collaborator(s): The primary mentor of this K23, Dr. Petri, has a 30-year record of NIH Funding and has mentored 10 prior K awardees, 6 of whom have already made the K to R transition. My mentors include experts in immunology, virology, childhood diarrheal disease and statistics. Environment and Institutional Commitment to the Candidate: The intellectual environment at UVA is robust. I have a strong commitment from my Department and Division assuring 90% protected research time regardless of the outcome of this K23 proposal, and support of my continued mentorship under Dr. Petri at UVA.", "keywords": [ "2 year old", "2019-nCoV", "5 year old", "Active immunity", "Address", "Adenovirus Protein", "Adenoviruses", "Advisory Committees", "Affect", "Antibodies", "Antibody Repertoire", "Antibody Response", "Antigens", "Bangladesh", "Bangladeshi", "Biometry", "Birth", "Cause of Death", "Child", "Childhood", "Clinical Trials Design", "Cohort Studies", "Communicable Diseases", "Data", "Data Analyses", "Development", "Development Plans", "Diarrhea", "Disease", "Enteral", "Environment", "Faculty", "Feces", "Fellowship", "Filtration", "Funding", "Goals", "Growth", "Health", "Human Milk", "Humoral Immunities", "Immune", "Immune Targeting", "Immune response", "Immunity", "Immunology", "Infant", "Infection", "Institution", "Internal Medicine", "International", "Intervention", "Knowledge", "Life", "Longitudinal cohort", "Maternal antibody", "Measures", "Mentors", "Mentorship", "Morbidity - disease rate", "Mothers", "Mucosal Immune Responses", "Mucous Membrane", "Outcome", "Passive Immunity", "Passive Transfer of Immunity", "Physicians", "Plasma", "Polymerase Chain Reaction", "Population", "Population Attributable Risks", "Protein Microchips", "Publishing", "Recurrent disease", "Reproducibility", "Research", "Research Institute", "Research Personnel", "Residencies", "Sampling", "Scholars Program", "Scientist", "Serum", "Testing", "Time", "Translational Research", "United States National Institutes of Health", "Universities", "Vaccination", "Viral", "Virginia", "Virus", "Work", "biobank", "career", "career development", "cohort", "cost effective", "design", "diarrheal disease", "efficacy evaluation", "enteric adenovirus infection", "enteric infection", "enteric pathogen", "infant infection", "innovation", "insight", "knowledge base", "low and middle-income countries", "low income country", "maternal vaccination", "member", "molecular diagnostics", "mortality", "neurodevelopment", "novel", "pandemic disease", "pathogen", "prevent", "professor", "recurrent infection", "response", "statistics", "stool sample", "translational health science", "translational scientist", "vaccination strategy", "vaccine development", "virology" ], "approved": true } }, { "type": "Grant", "id": "15649", "attributes": { "award_id": "2451399", "title": "SBIR Phase I: Novel Peptide Immunomodulators for Treatment of Autoimmune and Inflammatory Disorders", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase I" ], "program_reference_codes": [], "program_officials": [ { "id": 936, "first_name": "Henry", "last_name": "Ahn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": null, "award_amount": 305000, "principal_investigator": { "id": 32152, "first_name": "Masha", "last_name": "Fridkis-Hareli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2552, "ror": "", "name": "PALENA THERAPEUTICS, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is in developing a novel class of compounds capable of treating autoimmune and inflammatory conditions safely and effectively. With the constant threat of new COVID variants, influenza, and RSV, there is an unmet medical need for therapeutics that can effectively treat autoimmune diseases especially in pediatric patients without compromising the immune system to respond to infections. This problem has been overcome with the discovery of novel compositions that demonstrate efficacy equal or superior to many of the first line therapies used to treat immune diseases. The improved safety, efficacy and lower cost of these therapeutics should provide a significant benefit to patients by overall contributing to their quality of life as compared to current medications, as well as marketing and partnering advantage in its commercialization efforts, which will focus on rare diseases, such as juvenile idiopathic arthritis-associated uveitis and pediatric Crohn’s disease among others. In the era of socio-economic disparities, these affordable drugs will become available to the historically neglected low-income communities. If executed successfully, this proposal would validate the platform technology and demonstrate the feasibility of identifying candidates for further development into life-changing treatments. This Small Business Innovation Research (SBIR) Phase I project will demonstrate the unique design of novel compounds to augment and re-program the immune responses from pro- to anti-inflammatory, based on the binding to MHC class II molecules that leads to immunomodulation. The technical complexities of understanding the effects of peptide sequences on the outcomes of cellular interactions present challenges related to selecting the appropriate amino acids both for the random and specific components of these compositions. These hurdles will be addressed by design of several candidate compounds for each target condition, juvenile idiopathic arthritis-associated uveitis and pediatric Crohn’s disease, that will take into account the structure of autoantigenic peptides known to interact with both the MHC class II and T cell receptor (TCR). These candidate compounds will be initially tested in vitro in human macrophages to assess their potential to inhibit secretion of pro-inflammatory cytokines. Of these compounds, the most efficient ones will be tested for activity in relevant animal models. This approach will allow identifying and selecting the best drug candidates for further development into therapies for pediatric conditions as outlined above. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15601", "attributes": { "award_id": "1R13NS141592-01", "title": "2025 Patrica Levy Zusman International Workshop on Neuroregeneration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 24007, "first_name": "LINDA LOUISE", "last_name": "Bambrick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": "2026-02-28", "award_amount": 14000, "principal_investigator": { "id": 26852, "first_name": "Philip J", "last_name": "Horner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1455, "ror": "", "name": "METHODIST HOSPITAL RESEARCH INSTITUTE", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This R13 resulted from discussions between investigators in the fields of neurostimulation and neuroplasticity at the Houston Methodist Research Institute (HMRI). In 2017, we held an R13-funded pilot workshop that combined research in neural stimulation with new insight into the molecular understanding of neural plasticity and regeneration. The workshop received a strong, positive response by participants and interest in further catalysts for working collaboration. Thus, in 2019, we fostered relationship development and crossover opportunities among attendees via a blitz session wherein newly formed (i.e., established at the 2019 Workshop) collaborative teams competed for two $5K mini grants that supported travel to and from each other’s institutions. In 2021, we went 100% virtual due to COVID-19, however, this did not diminish the R13-funded Workshop’s impact. In 2023, our R13-funded workshop returned to an in-person event, bringing with it many of the successful virtual tools from 2021. On March 4th – 6th, 2025, we will host the 5th Patricia Levy Zusman International Workshop on Neuroregeneration (Zusman Workshop), which will focus on the intersection of electrical activity, brain connectomics, and molecular neural plasticity. Our specific aims are to: 1) formulate new ideas to fill the gap between physiology and functional-based brain stimulation technologies and the molecular and cellular understanding of innate neuronal plasticity; 2) provide promising trainees with various avenues to present their work; and 3) ensure trainees participate in substantial discussions and interactions with faculty members. The 2025 Workshop will be held at HMRI, which is part of the Texas Medical Center (TMC; a one-of-a-kind medical and research hub that fosters cross-institutional collaboration, creativity, and innovation) and is in Houston, Texas (one of the United States’ most diverse cities). A key aspect of the Zusman Workshop is the active inclusion and participation of trainees, particularly women and under-represented minorities. We will encourage their participation via travel scholarships and active promotion and recruitment throughout the TMC. The Workshop promotes the voices of graduate and postdoctoral trainees by including a trainee poster session as well as a session dedicated to trainee oral presentations (given by travel awardees). Further, goal-oriented breakout sessions, led by senior/early-stage investigators and selected trainees, will foster discussion and promote cross-training and collaboration among participants. Overall, this workshop distinguishes itself from established physiology conferences and dedicated neural regeneration conferences by being 1) highly focused on the gap between molecular regeneration and electrophysiology/stimulation, 2) concept driven by clinicians and experimentalists currently problem solving in human therapy, and 3) focused on the establishment of cross training and expertise development in graduate, post-graduate, and clinical fellows. The 2025 Zusman Workshop will ignite nascent collaborations and spur novel multidisciplinary teams to develop innovative, transdisciplinary methods, technologies, and treatments to modulate performance in the damaged nervous system.", "keywords": [ "Acceleration", "Address", "Adjuvant Therapy", "Award", "Back", "Basic Science", "Brain", "COVID-19", "Cells", "Central Nervous System", "Cities", "Clinical", "Collaborations", "Creativeness", "Dedications", "Development", "Devices", "Discipline", "Disease", "Educational workshop", "Electrodes", "Electrophysiology (science)", "Elements", "Ensure", "Event", "Faculty", "Feedback", "Fostering", "Frequencies", "Funding", "Funding Opportunities", "Goals", "Grant", "Health Sciences", "Human", "Institution", "International", "Laboratories", "Machine Learning", "Medical", "Medical center", "Medicine", "Mental Depression", "Mentors", "Methodist Church", "Methods", "Molecular", "Movement Disorders", "Natural regeneration", "Nerve Regeneration", "Nervous System Trauma", "Neuronal Plasticity", "Neuropsychology", "Oral", "Paralysed", "Participant", "Performance", "Persons", "Physical Rehabilitation", "Physicians", "Physiologic pulse", "Physiology", "Postdoctoral Fellow", "Problem Solving", "Productivity", "Research", "Research Institute", "Research Personnel", "Rice", "Schedule", "Scholarship", "Science", "Scientist", "Speed", "Stroke", "Study Section", "System", "Technology", "Texas", "Training", "Travel", "Underrepresented Minority", "United States", "United States National Institutes of Health", "Universities", "Virtual Tool", "Voice", "Woman", "Work", "brain based", "brain computer interface", "catalyst", "clinical application", "college", "combinatorial", "exoskeleton", "graduate student", "gulf coast", "improved", "innovation", "insight", "interdisciplinary collaboration", "interest", "lectures", "meetings", "member", "multidisciplinary", "neural", "neural stimulation", "neuromechanism", "neurophysiology", "neuroregulation", "novel", "post-doctoral training", "posters", "recruit", "regenerative therapy", "repaired", "response", "success", "symposium", "training opportunity", "translational approach", "virtual", "working group" ], "approved": true } }, { "type": "Grant", "id": "15599", "attributes": { "award_id": "1R01CA301643-01", "title": "Role of respiratory viral infections and inflammation in promoting metastatic outgrowth in the lung", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21648, "first_name": "Elizabeth Lee", "last_name": "Read-Connole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": "2030-02-28", "award_amount": 672011, "principal_investigator": { "id": 32096, "first_name": "James V", "last_name": "Degregori", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32097, "first_name": "Mercedes", "last_name": "Rincon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "The leading cause of breast cancer deaths is metastasis. Metastatic relapse can occur months to years after the initial diagnosis and treatment of the primary tumor. Cancer cells can disseminate from the primary tumor into different tissues including lungs and remain in a dormant state for years to decades. Awakening of these dormant disseminated cancer cells (DCC) leads to metastasis. Finding factors that trigger the awakening of dormant DCC and developing strategies to reduce the risk of awakening is therefore an unmet need. While it is known that inflammation is a key contributing factor to the awakening of dormant DCC, no studies have investigated whether inflammation triggered by viral respiratory infections (a very common infection worldwide) in the lung can promote the expansion of DCC and lead to the development of metastases. Our recent studies using a mouse model of breast cancer DCC dormancy in the lung have revealed a dramatic increase in DCC awakening and expansion in the lungs following influenza virus infection. Our data support the hypothesis that respiratory viral infections can promote DCC awakening and expansion through two phases: first, through IL-6 dependent DCC awakening and expansion, and second, CD4 T-cell mediated protection from elimination (in part by CD8 cells). We further show that infection with a mouse-adapted SARS-CoV-2 promotes a similar awakening and expansion of DCC in mice. Finally, epidemiological studies reveal how prior infection with SARS-CoV-2 infection increases metastatic progression in lungs and cancer- related deaths for cancer survivors. We propose to determine mechanisms by which acute respiratory viral infections induce the awakening of dormant DCC leading to metastatic disease, whether and how such infections can prime DCC for activation by subsequent exposures, and how CD4 and CD8 cells differentially control the persistence of expanded DCC during influenza virus infection. Impact: Proposed studies to understand how different pulmonary viral infections alter DCC dormancy and host immune responses, to determine the consequences for progression to metastatic disease, and to explore underlying mechanisms, should yield valuable and actionable insight into the key cell types and molecular mediators, informing early detection and prevention strategies for at-risk individuals.", "keywords": [ "2019-nCoV", "Acute", "Affect", "B-Lymphocytes", "Biological Markers", "Breast", "Breast Cancer Model", "Bronchus-Associated Lymphoid Tissue", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 pandemic", "Cancer Patient", "Cancer Survivor", "Cells", "Cessation of life", "Data", "Development", "Diagnosis", "Disease", "Early Diagnosis", "Epidemic", "Epithelial Cells", "Genetic Transcription", "IL6 gene", "Immune", "Immune response", "Individual", "Infection", "Inflammation", "Inflammatory", "Influenza", "Interleukin-6", "Intervention", "Link", "Lung", "Lung infections", "Lymphocytic choriomeningitis virus", "Lymphoid Tissue", "Maintenance", "Malignant Breast Neoplasm", "Malignant Neoplasms", "Malignant neoplasm of lung", "Mediating", "Mediator", "Mesenchymal", "Metastatic Neoplasm to the Lung", "Metastatic/Recurrent", "Modeling", "Molecular", "Mus", "Neoplasm Metastasis", "Pathway interactions", "Persons", "Phase", "Phenotype", "Prevalence", "Prevention strategy", "Primary Neoplasm", "Proliferating", "Relapse", "Research", "Respiratory Tract Infections", "Risk", "Risk Reduction", "Role", "SARS-CoV-2 infection", "Seasons", "Signal Pathway", "Signal Transduction", "Source", "Testing", "Tissues", "Upregulation", "Viral", "Viral Respiratory Tract Infection", "Virus", "Virus Diseases", "cancer cell", "cell type", "cigarette smoking", "cytokine", "epidemiology study", "experience", "influenza infection", "influenzavirus", "insight", "mouse model", "pandemic disease", "prevent", "programs", "progression risk", "respiratory", "response", "risk mitigation", "seasonal influenza" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1392, "count": 13920 } } }